Skip to main content
ELDN
NASDAQ Life Sciences

Eledon's Tegoprubart Shows 100% Insulin Independence in Diabetes Study; Q1 Net Loss Widens

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$3.83
Mkt Cap
$294.305M
52W Low
$1.35
52W High
$4.6
52W Position info
184% above low
Off High info
17% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ELDN has more than doubled off its 52-week low of $1.35.

Summary

Eledon Pharmaceuticals reported its first quarter 2026 financial results and significant business highlights for its lead candidate, tegoprubart. The most impactful news is the achievement of 100% insulin independence in 10 patients with type 1 diabetes following islet transplantation in a UChicago Medicine-led study, alongside positive 24-month follow-up data from a Phase 1b kidney transplantation trial and FDA Orphan Drug designation for liver transplantation. Financially, the company reported a widened net loss of $39.0 million, or $0.33 per share, for Q1 2026, primarily driven by a $19.0 million non-cash loss from warrant liabilities. Cash, cash equivalents, and short-term investments totaled $111.1 million as of March 31, 2026, with a projected runway into Q2 2027. This cash position and burn rate reinforce the context of the $500 million universal shelf registration (S-3) filed on May 1st. The strong clinical data, particularly the 100% insulin independence, is a significant positive catalyst for a clinical-stage biotech, validating tegoprubart's potential and de-risking its development. Investors will now watch for upcoming FDA guidance on Phase 3 kidney transplantation trials and regulatory discussions for islet cell transplantation.

At the time of this announcement, ELDN was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $294.3M. The 52-week trading range was $1.35 to $4.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ELDN - Latest Insights

ELDN
Nov 12, 2026, 4:35 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $1.95 info
Change: -$0.460 (-19%) info
Market Cap: $167.23M info
ELDN
Nov 12, 2026, 4:30 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.41
Real-time Price: $1.95 info
Change: -$0.460 (-19%) info
Market Cap: $167.23M info
ELDN
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.41
Real-time Price: $1.95 info
Change: -$0.460 (-19%) info
Market Cap: $167.23M info
ELDN
Oct 26, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.31
Real-time Price: $1.95 info
Change: -$0.360 (-16%) info
Market Cap: $167.23M info
ELDN
Sep 22, 2026, 1:48 PM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $1.95 info
Change: -$0.935 (-32%) info
Market Cap: $167.23M info